Evidence map›Paper›PMID 40683864›Full record

ArticleNature communications2025

Nanomechanical binding mechanism of ligands drives agonistic activity.

Hannah Seferovic, Patricia Sticht, Lisa Hain, Rong Zhu, Sebastian Diethör, Christian Wechselberger, Florian Weber, David Bernhard, Birgit Plochberger, Yoo Jin Oh and 2 more

Abstract read
In one paragraph

Article in Nature communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hannah SeferovicInstitute of Biophysics, Johannes Kepler University, Linz, Austria.ORCID http://orcid.org/0000-0002-8551-8321
Patricia StichtInstitute of Biophysics, Johannes Kepler University, Linz, Austria.
Lisa HainInstitute of Biophysics, Johannes Kepler University, Linz, Austria.
Rong ZhuInstitute of Biophysics, Johannes Kepler University, Linz, Austria.ORCID http://orcid.org/0000-0001-7553-7249
Sebastian DiethörInstitute of Biophysics, Johannes Kepler University, Linz, Austria.
Christian WechselbergerDivision of Pathophysiology, Institute of Physiology and Pathophysiology, Medical Faculty, Johannes Kepler University, Linz, Austria.
Florian WeberDepartment of Medical Engineering, Upper Austria University of Applied Sciences, Linz, Austria.ORCID http://orcid.org/0000-0002-8946-1377
David BernhardDivision of Pathophysiology, Institute of Physiology and Pathophysiology, Medical Faculty, Johannes Kepler University, Linz, Austria.
Birgit PlochbergerDepartment of Medical Engineering, Upper Austria University of Applied Sciences, Linz, Austria.ORCID http://orcid.org/0000-0003-2733-9947
Yoo Jin OhInstitute of Biophysics, Johannes Kepler University, Linz, Austria.ORCID http://orcid.org/0000-0002-9636-3329
Javier Chaparro-RiggersBioMedicine Design, Pfizer Inc, San Diego, California, USA.ORCID http://orcid.org/0000-0002-5403-966X
Peter HinterdorferInstitute of Biophysics, Johannes Kepler University, Linz, Austria. peter.hinterdorfer@jku.at.ORCID http://orcid.org/0000-0003-2583-1305

Funding

Austrian Science Fund (Fonds zur Förderung der Wissenschaftlichen Forschung) P30314
6 · The paper itself

Abstract

Monoclonal antibodies and ligands targeting CD40 exhibit a wide range of agonistic activities and antitumor responses. Studies have shown that the flexibility and affinity of antibodies play a crucial role in their immunostimulatory activity. However, a systematic comparison with the natural ligand is yet missing and a detailed investigation with respect to molecular rigidity, binding kinetics, and bond lifetime has not been undertaken to date. Here, we study the dynamic binding features of clinically relevant anti-hCD40 antibody subclasses, ChiLob 7/4, and the trimeric human CD40L to hCD40 at the single-molecule level. We visualize resembling of hCD40 receptors into dimers and higher-order oligomers that are dynamically captured and released by both ChiLob 7/4 and hCD40L with their multiple binding sites. Thereby, ChiLob 7/4 acts as a nanomechanical calliper and rotates its Fab arms in a highly dynamic fashion to screen for hCD40 binding, while hCD40L undergoes significantly less conformational changes. Despite its minor molecular flexibility, hCD40L performs association, dissociation, and re-association of hCD40 ten times faster when compared to ChiLob 7/4. We uncover a distinct binding mechanism that may explain the enhanced cluster formation potential and agonistic activity of the natural ligand and will inspire the design of novel ligand formats.

Indexed as

Antibodies, MonoclonalCD40 AntigensCD40 LigandBinding SitesHumansKineticsLigandsProtein BindingSingle Molecule ImagingAntibodies, MonoclonalCD40 AntigensCD40 LigandLigands

Identifiers

PMID40683864
PMCPMC12276331

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.